Related references
Note: Only part of the references are listed.Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC)
Rui Cao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
Alexandre F. Aissa et al.
NATURE COMMUNICATIONS (2021)
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Peter T. Harrison et al.
SEMINARS IN CANCER BIOLOGY (2020)
An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis
Suzie K. Hight et al.
NEOPLASIA (2020)
Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients
Zihao Wang et al.
Aging-US (2020)
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis
Francesco Agustoni et al.
CANCER TREATMENT REVIEWS (2019)
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Amira A. Barkal et al.
NATURE (2019)
The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer
Nadege Bercovici et al.
FRONTIERS IN IMMUNOLOGY (2019)
Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
Ayan Tyagi Kumar et al.
FRONTIERS IN ONCOLOGY (2019)
The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress
Laura Moreno Leon et al.
ONCOGENE (2019)
Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response
Yangyang Qi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Mining TCGA database for genes of prognostic value in glioblastoma microenvironment
Di Jia et al.
AGING-US (2018)
Identifying cell populations with scRNASeq
Tallulah S. Andrews et al.
MOLECULAR ASPECTS OF MEDICINE (2018)
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Andrew Butler et al.
NATURE BIOTECHNOLOGY (2018)
Ovarian cancer stem cells: still an elusive entity?
Michela Lupia et al.
MOLECULAR CANCER (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology
Han-xiang Zhan et al.
CANCER LETTERS (2017)
CTLA-4 blockade in the treatment of rheumatoid arthritis: an update
Maurizio Cutolo et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression
Wenjing Mu et al.
CELL RESEARCH (2015)
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf et al.
NATURE (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Patients
Hao Tang et al.
CLINICAL CANCER RESEARCH (2013)
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Matthew J. Niederst et al.
SCIENCE SIGNALING (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment
Jeremy Chien et al.
FRONTIERS IN ONCOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Adam D. Steg et al.
CLINICAL CANCER RESEARCH (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kai Kessenbrock et al.
CELL (2010)
Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells
Niels Eckstein et al.
CANCER RESEARCH (2009)
mRNA-Seq whole-transcriptome analysis of a single cell
Fuchou Tang et al.
NATURE METHODS (2009)
Genetical toxicogenomics in Drosophila identifies master-modulatory loci that are regulated by developmental exposure to lead
Douglas M. Ruden et al.
NEUROTOXICOLOGY (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses
Guo-Yun Chen et al.
SCIENCE (2009)
Measures to assess the prognostic ability of the stratified Cox proportional hazards model
J. Danesh et al.
STATISTICS IN MEDICINE (2009)
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance
Mark B. Meads et al.
CLINICAL CANCER RESEARCH (2008)
Adaptive lasso for Cox's proportional hazards model
Hao Helen Zhang et al.
BIOMETRIKA (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
